Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Type 2 diabetes and cardiovascular disease

Journal articles and book chapters

06-20-2018 | Cardiovascular outcomes | Article

Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: A meta-analysis of cardiovascular outcomes trials

Wang Q et al. Diabetes Res Clin Prac 2018; 143: 34–42. doi: 10.1016/j.diabres.2018.06.009

06-16-2018 | Medications | Review | Article

Availability and affordability of essential medicines: Implications for global diabetes treatment

Beran D et al. Curr Diab Rep 2018; 18: 48. doi: 10.1007/s11892-018-1019-z

06-16-2018 | Cardiovascular disorders | Review | Article

Inpatient glycemic management of non-cardiac CVD: Focus on stroke and PVD

Everett E, Mathioudakis N. Curr Diab Rep 2018; 18: 49. doi: 10.1007/s11892-018-1026-0

06-15-2018 | Semaglutide | Article

Semaglutide s.c. once-weekly in type 2 diabetes: A population pharmacokinetic analysis

Carlsson Petri KC et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0458-5

06-14-2018 | Hypoglycemia | Article

Hypoglycemia, cardiovascular outcomes, and death: The LEADER experience

Zinman B et al. Diabetes Care 2018: dc172677. doi: 10.2337/dc17-2677

06-12-2018 | Empagliflozin | Article

Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: Systematic literature review and indirect comparisons

Balijepalli C et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0456-7

06-09-2018 | Cardiovascular disorders | Review | Article

Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA

Khat DZ, Husain M. Curr Diab Rep 2018; 18: 45. doi: 10.1007/s11892-018-1011-7

06-08-2018 | Insulin resistance | Review | Article

Chronic kidney disease-induced insulin resistance: Current state of the field

Dave N, Wu J, Thomas S. Curr Diab Rep 2018; 18: 44. doi: 10.1007/s11892-018-1010-8

06-08-2018 | Cardiovascular disorders | Review | Article

Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007–2017

Einarson TR et al. Cardiovasc Diabetol 2018; 17: 83. doi: 10.1186/s12933-018-0728-6

06-06-2018 | Mental health | Article

The relationship between sleep and cognitive function in patients with prediabetes and type 2 diabetes

Saetung S et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1166-3

06-05-2018 | Cardiovascular outcomes | Review | Article

Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: A comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

Zhuang X et al. Cardiovasc Diabetol 2018; 17: 79. doi: 10.1186/s12933-018-0722-z

06-04-2018 | Pediatrics | Review | Article

Identifying prediabetes and type 2 diabetes in asymptomatic youth: Should HbA1c be used as a diagnostic approach?

Vajravelu ME, Lee JM. Curr Diab Rep 2018; 18: 43. doi: 10.1007/s11892-018-1012-6

06-01-2018 | DPP-4 inhibitors | Article

Comparative effectiveness of DPP-4 inhibitors versus sulfonylurea for the treatment of type 2 diabetes in routine clinical practice: A retrospective multicenter real-world study

Fadini GP et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0452-y

06-01-2018 | Atherosclerosis | Article

Diabetes and trajectories of estimated glomerular filtration rate: A prospective cohort analysis of the Atherosclerosis Risk in Communities study

Warren B et al. Diabetes Care 2018. doi: 10.2337/dc18-0277

06-01-2018 | Obesity | Article

Weight loss and mortality risk in patients with different adiposity at diagnosis of type 2 diabetes: A longitudinal cohort study

Adjah Owusu ES et al. Nutr Diabetes 2018; 8: 37. doi: 10.1038/s41387-018-0042-0

05-30-2018 | Cardiovascular outcomes | Article

Serial measurement of natriuretic peptides and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE trial

Jarolim P et al. Diabetes Care 2018. doi: 10.2337/dc18-0109

05-28-2018 | Sulfonylureas | Article

Meta-analysis of sulfonylurea therapy on long-term risk of mortality and cardiovascular events compared to other oral glucose-lowering treatments

Powell WR, Christiansen CL, Miller DR. Diabetes Ther 2018. doi: 10.1007/s13300-018-0443-z

05-28-2018 | Risk factors | Article

Diabetes risk scores for Hispanics living in the United States: A systematic review

Juarez LD et al. Diabetes Res Clin Prac 2018. doi: 10.1016/j.diabres.2018.05.009

05-25-2018 | Oral combination medications | Article

Characterization of the open-label lead-in period of two randomized controlled phase 3 trials evaluating dapagliflozin, saxagliptin, and metformin in type 2 diabetes

Mathieu C et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0445-x

05-24-2018 | Diet | Article

Intake of cocoa products and risk of type-2 diabetes: The multiethnic cohort

Maskarinec G et al. Eur J Clin Nutr 2018. doi: 10.1038/s41430-018-0188-9

Next Previous
Image Credits